Collaboration. Navigation. Innovation.
Early results from clinical study
Southlake Regional Health Centre is the leading Canadian research site for the first phase of the Foresight ICE trial.
“The Foresight ICE has provided us a new option for guiding trans-septal puncture and I see potential in the 3D imaging that we will be able to take advantage of in several EP and structural cases.”Dr. Atul Verma
Director Arrhythmia Services
Southlake Regional Health Centre
Novasight Hybrid System Receives FDA 510(k) Clearance
Conavi has received 510(k) clearance from the US Food and Drug Administration (FDA) for our Novasight Hybrid System. The system enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during angioplasty and stenting procedures.
Foresight ICE™ System Receives Clearance for New Features
Conavi is pleased to announce 510(k) clearance from the FDA for our Foresight ICE System expanded feature set. The enhancements include Color Doppler, Pulsed-Wave Doppler, 2D and 3D measurements, and ECG-gated 3D image acquisition.
Foresight ICE™ System
Our Foresight ICE™ System stands as the first intracardiac echo system capable of acquiring 2D and 3D images with a full 360° field-of-view.
|Watch System Demonstration|
MedTech Innovator Selects Conavi for 2018 Showcase
Conavi Medical is pleased to announce that we are among the 50 companies selected by MedTech Innovator to participate in the organization’s 2018 showcase. MedTech Innovator is a non-profit organization designed to identify and support innovative early-stage medical device companies. As part of our selection, the Conavi team will attend several MedTech Innovator conferences and events to pursue opportunities for mentorship and financial support from healthcare industry leaders.
Read more here.
Conavi Enters into Distribution Agreement with China Grand Pharmaceutical and Healthcare
Conavi is pleased to announce that we have entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of our Foresight ICE System and Novasight Hybrid System in China, Hong Kong, Taiwan and Macau.
Dr. Brian Courtney, Conavi’s President and Chief Executive Officer, states that “This agreement represents an important commercial milestone for Conavi. China has the second largest volume of cardiovascular interventional procedures in the world and is growing quickly as a result of extensive investments in healthcare infrastructure. We are delighted to have found a partner that shares our vision of bringing the potential benefits of advanced image guidance to a broad range of existing and emerging minimally invasive cardiovascular procedures to patients in China.”
Conavi’s Foresight ICE System has received 510(k) clearances from the United States Food & Drug Administration (FDA) and a Medical Device License from Health Canada and is currently being marketed in North America. The Novasight Hybrid System combines the two most frequently used intravascular imaging technologies, intravascular ultrasound (IVUS) and optical coherence tomography (OCT), into a single catheter and platform. The Novasight Hybrid System has been submitted to the US FDA for 510(k) clearance.
Conavi Partners with Nova Scotia Health Authority and Government of Canada to Advance Patient Care
Conavi is pleased to announce that we are spearheading a collaborative effort to develop an imaging and tissue cutting probe for guided cardiovascular surgeries. The miniaturized probe leverages ultrasound technology for both imaging and precision cutting, allowing physicians to diagnose and treat serious conditions in a minimally invasive manner.
The Government of Canada is investing $2.6+ million over five years in the Nova Scotia Health Authority (NSHA) to develop the endoscope prototype. Throughout the development, Conavi will lend our medical and technological expertise to assist the NSHA in taking the solution from concept to creation. Upon creation, Conavi will commercialize the solution for cardiovascular surgical applications, allowing patients worldwide to benefit from improved clinical outcomes.
Fellow Toronto-based company Synaptive Medical will also assist in developing the solution and will likewise commercialize the solution for neurological applications.
Read more here.
It's clear that there's a need. We have a path to get there.Dr. Brian Courtney